Link Pharma Chem re-appoints Satish Thakur as Chairman

Link Pharma Chem Limited has announced the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director of the company. The decision is subject to the approval of shareholders at the ensuing Annual General Meeting. The disclosure was made in compliance with SEBI regulations.

Mr. Thakur is scheduled to assume office on June 24, 2026. His tenure will extend for a period of three years from the date of appointment. He has been associated with link pharma chem since its incorporation and holds a B.Sc. and L.Tech degree.

The director brings extensive experience to the role, with over 43 years in the industry. His expertise includes project design and development. He has been involved in the operations of the company since its inception.

Key Appointment Details

Sr. No.	Disclosure Requirement	Details
01.	Reason for change	Re-appointment of Mr. Satish G Thakur (DIN: 00292129) as Chairman and Whole-time Director.
02.	Date of appointment & term	June 24, 2026, for a period of 3 years subject to shareholder approval.
03.	Brief profile	Associated with the company since incorporation; holds B.Sc., L.Tech; over 43 years of experience.
04.	Relationship	Father of Mr. Rishikesh Thakur, Managing Director.

The company's registered office is located at Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat).

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-3.57%	-9.27%	-19.21%	-24.58%	-27.61%

Link Pharma Chem Limited has reported its audited financial results for the quarter and financial year ended March 31, 2026. The company returned to profitability for the full fiscal year, recording a net profit of ₹7.69 crore compared to a net loss of ₹102.73 crore in the previous year. Revenue from operations for the year ended March 31, 2026, stood at ₹2,743.15 crore, up from ₹2,543.34 crore in the corresponding period of the previous year. Total income for the year rose to ₹2,763.49 crore from ₹2,561.99 crore in FY25.

Board Re-appoints Managing Director

The Board of Directors of Link Pharma Chem Limited at its meeting held on May 21, 2026, re-appointed Mr. Rishikesh Thakur as the Managing Director of the company for a further period of three years with effect from September 24, 2026. This appointment is subject to the approval of shareholders at the ensuing Annual General Meeting. Mr. Rishikesh Thakur holds a B. Eng. in Polymer from London Metropolitan University and possesses over 15 years of experience in the chemical business, including manufacturing, R&D, and project development. He is the son of Mr. Satish G. Thakur, the Chairman & Whole-time Director of the company.

Financial Performance for FY26

The company's total expenses for the year increased marginally to ₹2,749.98 crore from ₹2,702.24 crore in the previous year. Profit before tax for the year was recorded at ₹13.51 crore, a significant improvement from the loss before tax of ₹140.25 crore in FY25. The finance costs for the year reduced to ₹52.98 crore from ₹77.55 crore in the prior year.

Quarterly Results

For the quarter ended March 31, 2026, the company reported a net loss of ₹40.86 lakh, compared to a net loss of ₹35.02 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter stood at ₹658.88 crore, slightly higher than the ₹644.66 crore reported in the same period last year. Total expenses for the quarter increased to ₹722.62 crore from ₹704.72 crore in Q4 FY25.

Key Financial Metrics

The following table summarizes the audited financial results for Link Pharma Chem Limited for the year and quarter ended March 31, 2026:

Particulars	Year Ended Mar 31, 2026 (₹ in Lakhs)	Year Ended Mar 31, 2025 (₹ in Lakhs)	Quarter Ended Mar 31, 2026 (₹ in Lakhs)	Quarter Ended Mar 31, 2025 (₹ in Lakhs)
Revenue from operations	2,743.15	2,543.34	658.88	644.66
Total Income	2,763.49	2,561.99	673.62	656.45
Total Expenses	2,749.98	2,702.24	722.62	704.72
Profit/(Loss) before tax	13.51	(140.25)	(49.00)	(48.27)
Net Profit/(Loss) for the period	7.69	(102.73)	(40.86)	(35.02)

Assets and Liabilities

As of March 31, 2026, the company's total assets stood at ₹2,496.22 crore, compared to ₹2,329.32 crore in the previous year. Total equity increased to ₹1,278.92 crore from ₹1,266.21 crore. Cash and cash equivalents improved significantly to ₹54.59 crore as of March 31, 2026, from ₹6.45 crore in the prior year. The company's operations fall under a single segment, namely the manufacture and sale of chemicals.